middle.news
Resonance Health Advances Non-Invasive Liver Fibrosis MRI Device Amid FY26 Growth
9:43am on Tuesday 9th of June, 2026 AEST
•
Healthcare
Read Story
Resonance Health Advances Non-Invasive Liver Fibrosis MRI Device Amid FY26 Growth
9:43am on Tuesday 9th of June, 2026 AEST
Key Points
MRI Liver Fibrosis device in late-stage clinical validation
No FY26 revenue expected from fibrosis device, early trial use planned
Profitable SaaMD platform with 400+ active MRI sites globally
Strong FY26 guidance: $16M revenue, 14% EBITDA margin
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Resonance Health (ASX:RHT)
OPEN ARTICLE